ARYL-QUINOLYL COMPOUNDS AND THEIR USE

The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain aryl-quinolyl compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF) activity. The present invention also pertains...

Full description

Saved in:
Bibliographic Details
Main Authors SPRINGER, CAROLINE JOY, MARAIS, RICHARD, NICULESCU-DUVAZ, ION, ZAMBON, ALFONSO, NICULESCU-DUVAZ, DAN, WHITTAKER STEVEN
Format Patent
LanguageEnglish
French
Published 29.10.2009
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain aryl-quinolyl compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc. La présente invention se rapporte de manière générale au domaine des composés thérapeutiques destinés au traitement des troubles prolifératifs, du cancer, etc., et de manière plus spécifique à certains composés aryl-quinoléyle, tels que décrits dans ce document, qui, entre autres, inhibent l'activité de RAF (par exemple, B-RAF). La présente invention concerne également des compositions pharmaceutiques renfermant de tels composés et l'utilisation de tels composés et compositions, à la fois in vitro et in vivo, pour inhiber l'activité de RAF (par exemple, B-RAF), pour inhiber l'activité de récepteurs tyrosine kinase (RTK), pour inhiber la prolifération cellulaire et dans le traitement de maladies et de troubles qui sont améliorés par l'inhibition de RAF, RTK, etc., de troubles prolifératifs tels que le cancer (par exemple, un cancer colorectal, un mélanome), etc.
Bibliography:Application Number: WO2009GB01077